IMU - Imuniti Applies For Ethics Approval To Condu
IMU
IMU
IMU - Imuniti Applies For Ethics Approval To Conduct Clinical Trials On One Of
Its Products
Imuniti Holdings Limited
(Incorporated in the Republic of South Africa)
(Registration number: 2004/002282/06)
(previously Nungu Trading 83 Limited)
Share code: IMU & ISIN: ZAE000089199
("Imuniti" or "the Company")
IMUNITI APPLIES FOR ETHICS APPROVAL TO CONDUCT CLINICAL TRIALS ON ONE OF ITS
PRODUCTS
Protocols to test the Imuniti Nutritional Supplement Combo Pack, a product in
the Imuniti product portfolio, have been developed by the Medical Research
Council. These trials have been developed to demonstrate the efficacy and
safety of the product. The Imuniti Nutritional Supplement Combo Pack is a
combination of various products, which have been developed to supplement
the human body`s macro and micro nutrient requirements as well as to
enhance its immune capabilities.
Imuniti`s decision to conduct clinical trials on "The Pack" follows the
extremely positive anecdotal results reported by users of "The Pack", over
a period of three years. The results gathered over this period have
demonstrated "The Pack`s" enhanced immune boosting capabilities with
respect to the general well being of users and, in particular, the well
being of HIV/AIDS and TB suffers who have used "The Pack".
The newly-designed protocols developed by the Medical Research Council for the
testing of the Imuniti Group`s Imuniti Nutritional Supplement Combo Pack,
have been approved by the Peer Review Committee of the Medical Control
Council. They have now been submitted to the Ethics Committee of the
Medical Research Council for their approval.
Pretoria
17 April 2007
Designated Adviser
Exchange Sponsors (Pty) Ltd
Date: 17/04/2007 11:52:46 Produced by the JSE SENS Department.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
